These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 18407142)

  • 1. Immunotherapy at clinical diagnosis of insulin-dependent diabetes: an approach still worth considering.
    Pozzilli P; Maclaren NK
    Trends Endocrinol Metab; 1993 Apr; 4(3):101-5. PubMed ID: 18407142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in the immunointervention of type-1 diabetes mellitus.
    Schernthaner G
    Horm Metab Res; 1995 Dec; 27(12):547-54. PubMed ID: 8750784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fasting plasma glucose after intensive insulin therapy predicted long-term glycemic control in newly diagnosed type 2 diabetic patients.
    Liu J; Liu J; Fang D; Liu L; Huang Z; Wan X; Cao X; Li Y
    Endocr J; 2013; 60(6):725-32. PubMed ID: 23428844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell mediated therapy for immunoregulation of type 1 diabetes mellitus.
    Phillips BE; Giannoukakis N; Trucco M
    Pediatr Endocrinol Rev; 2008 Jun; 5(4):873-9. PubMed ID: 18552749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long-term follow-up study.
    Xu W; Li YB; Deng WP; Hao YT; Weng JP
    Chin Med J (Engl); 2009 Nov; 122(21):2554-9. PubMed ID: 19951569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.
    Ogawa N; List JF; Habener JF; Maki T
    Diabetes; 2004 Jul; 53(7):1700-5. PubMed ID: 15220193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX).
    Crinò A; Schiaffini R; Manfrini S; Mesturino C; Visalli N; Beretta Anguissola G; Suraci C; Pitocco D; Spera S; Corbi S; Matteoli MC; Patera IP; Manca Bitti ML; Bizzarri C; Pozzilli P;
    Eur J Endocrinol; 2004 May; 150(5):719-24. PubMed ID: 15132730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?
    van Raalte DH; Verchere CB
    Diabetes Obes Metab; 2017 Sep; 19(9):1205-1213. PubMed ID: 28295962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type II diabetes mellitus.
    Edelman SV
    Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice.
    Besançon A; Goncalves T; Valette F; Dahllöf MS; Mandrup-Poulsen T; Chatenoud L; You S
    Diabetologia; 2018 Feb; 61(2):389-398. PubMed ID: 29030662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effects of early intensive therapy on islet beta cell function and long-term glycemia control in newly diagnosed type 2 diabetic patients with different fasting plasma glucose levels.].
    Li YB; Zeng LY; Shi LX; Zhu DL; Zhou ZG; Yan L; Tian HM; Luo ZJ; Yang LY; Liu J; Weng JP
    Zhonghua Nei Ke Za Zhi; 2010 Jan; 49(1):9-13. PubMed ID: 20356473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactin as an Adjunct for Type 1 Diabetes Immunotherapy.
    Hyslop CM; Tsai S; Shrivastava V; Santamaria P; Huang C
    Endocrinology; 2016 Jan; 157(1):150-65. PubMed ID: 26512750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose evaluation trial for remission (GETREM) in type 1 diabetes: a European multicentre study.
    Pozzilli P; Manfrini S; Buzzetti R; Lampeter E; Leeuw ID; Iafusco D; Prisco M; Ionescu-Tirgoviste C; Kolouskovà S; Linn T; Ludvigsson J; Madàcsy L; Mrozikiewicz AS; Mrozikiewicz PM; Podar T; Vavrinec J; Vialettes B; Visalli N; Yilmaz T; Browne PD;
    Diabetes Res Clin Pract; 2005 Jun; 68(3):258-64. PubMed ID: 15936469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune and cell therapy in type 1 diabetes: too little too late?
    Gillard P; Mathieu C
    Expert Opin Biol Ther; 2011 May; 11(5):609-21. PubMed ID: 21406028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
    Wolffenbuttel BH; van Haeften TW
    Drugs; 1995 Aug; 50(2):263-88. PubMed ID: 8521759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus].
    Ozawa H; Murai Y; Ozawa T
    Yakushigaku Zasshi; 2003; 38(1):11-27. PubMed ID: 14570054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Type 1 diabetes mellitus].
    Larger E; Dubois-Laforgue D; Timsit J
    Presse Med; 1999 Nov; 28(34):1895-903. PubMed ID: 10587728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal B-cell function in rats with non-insulin-dependent diabetes induced by neonatal streptozotocin: effect of in vivo insulin, phlorizin, or vanadate treatments.
    Serradas P; Bailbé D; Blondel O; Portha B
    Pancreas; 1991 Jan; 6(1):54-62. PubMed ID: 1994380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.